MedTrace Logo

Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies

NCT05123352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-11-17

No results posted yet for this study

Summary

In this observational single-center cohort study, metagenomic Next-Generation Sequencing (mNGS) will be used to investigate the features and changes of gut microbiota in acute myeloid leukemia (AML) patients during the treatment of two different induction therapy regimens \[standard intensive chemotherapy (7+3) or bcl-2 inhibitor-based targeted therapy\].

Conditions

Interventions

OTHER

collection of biological samples and clinical data

blood and feces samples

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Suning Chen, professor · The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2022-06-30
Completion
2022-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05123352 on ClinicalTrials.gov